XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Equity Securities
9 Months Ended
Sep. 30, 2020
Marketable Securities [Abstract]  
Marketable Equity Securities

5. Marketable Equity Securities

 

Marketable securities in equity securities with readily determinable market prices consisted of the following as of September 30, 2020 and December 31, 2019:

 

    Marketable equity securities at September 30, 2020  
          Gross unrealized     Gross realized        
    Cost     gains     gains (losses)     Fair value  
Common shares   $ 301,960     $ 84,516     $     $ 386,476  

 

    Marketable equity securities at December 31, 2019  
          Gross unrealized     Gross realized        
    Cost     gains     gains (losses)     Fair value  
Common shares   $ 423,025     $ 216,622     $     $ 639,647  

 

The following table presents additional information about marketable equity securities:

 

    Marketable  
    Equity Securities  
Balance at January 1, 2020   $ 639,647  
Sales of marketable equity securities     (143,667 )
Realized gains on marketable equity securities     22,602  
Unrealized losses on marketable equity securities     (132,106 )
Balance at September 30, 2020   $ 386,476  

 

At September 30, 2020 and December 31, 2019, the Company had invested in the marketable equity securities of certain publicly traded companies. During the three and nine months ended September 30, 2020, unrealized losses of $184,419 and $132,106, respectively, were included in net income as a component of change in fair value of equity securities. During the year ended December 31, 2019, the Company recognized unrealized gains of $258,905. The Company’s investment in marketable equity securities will be revalued on each balance sheet date. The fair value of the Company’s holdings in marketable equity securities at September 30, 2020 and December 31, 2019 is a Level 1 measurement based on quoted prices in an active market.

 

At September 30, 2020 and December 31, 2019, the Company also held equity investments in private companies and an investment in a limited partnership. These investments do not have readily determinable fair values and have been measured at cost less impairment, if any, and adjusted for observable price changes for identical or similar investments of the issuer.